FDA Commissioner Highlights New Rare Disease Framework Emphasizing Patient Voice

Acting US Food and Drug Administration (FDA) Commissioner Kyle Diamantas highlighted the agency's new rare disease framework during a fireside chat at the NORD Breakthrough Summit.

The framework is designed to modernize the development of orphan therapies and to incorporate the patient voice into scientific reviews.

Diamantas called the approach the best mechanism for advancing rare disease treatments, underscoring the FDA's commitment to patient-centered development.